BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 98 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $190,629 | -57.2% | 28,623 | +19.8% | 0.00% | 0.0% |
| Q1 2023 | $445,862 | -63.4% | 23,894 | -57.8% | 0.00% | -75.0% |
| Q4 2022 | $1,216,541 | +48.5% | 56,636 | -18.3% | 0.00% | +33.3% |
| Q3 2022 | $819,000 | -27.8% | 69,329 | -19.3% | 0.00% | 0.0% |
| Q2 2022 | $1,134,000 | +17.4% | 85,933 | +86.0% | 0.00% | +50.0% |
| Q1 2022 | $966,000 | +214.7% | 46,200 | +206.0% | 0.00% | +100.0% |
| Q4 2021 | $307,000 | -33.0% | 15,100 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $458,000 | +4.3% | 15,100 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $439,000 | -32.7% | 15,100 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $652,000 | -33.4% | 15,100 | -28.8% | 0.00% | -50.0% |
| Q4 2020 | $979,000 | -8.6% | 21,200 | -14.2% | 0.00% | -33.3% |
| Q3 2020 | $1,071,000 | +56.6% | 24,700 | +91.5% | 0.00% | +50.0% |
| Q2 2020 | $684,000 | +186.2% | 12,900 | +20.6% | 0.00% | +100.0% |
| Q1 2020 | $239,000 | – | 10,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |